Cirrhosis primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[Prevention (medical)|Primary prevention]] of [[cirrhosis]] includes avoidance of causative agents such as [[alcohol]], high doses of certain supplements ([[vitamin A]], [[copper]] and [[iron]]) and [[vaccination]] against [[hepatitis]]. Adequate caloric intake, physical activity, prevention of high risk behaviors, screening of blood products and vaccination for [[Hepatitis B]] play an important role in [[Prevention (medical)|primary prevention]]. | [[Prevention (medical)|Primary prevention]] of [[cirrhosis]] includes avoidance of causative agents such as [[alcohol]], high doses of certain supplements ([[vitamin A]], [[copper]] and [[iron]]) and [[vaccination]] against [[hepatitis]]. Adequate caloric intake, physical activity, prevention of high risk behaviors, [[Screening (medicine)|screening]] of blood products and vaccination for [[Hepatitis B]] play an important role in [[Prevention (medical)|primary prevention]]. | ||
==Primary Prevention== | ==Primary Prevention== | ||
| Line 21: | Line 21: | ||
** Education about [[hepatotoxins]] such as [[acetaminophen]] | ** Education about [[hepatotoxins]] such as [[acetaminophen]] | ||
** Prevention of [[obesity]] | ** Prevention of [[obesity]] | ||
** Screening of blood donors for [[Hepatitis B]], [[Hepatitis C]] | ** [[Screening (medicine)|Screening]] of blood donors for [[Hepatitis B]], [[Hepatitis C]] | ||
** Familial screening for [[Wilson's disease]], [[hemochromatosis]] | ** Familial screening for [[Wilson's disease]], [[hemochromatosis]] | ||
** Reduction of high-risk behaviors such as : | ** Reduction of high-risk behaviors such as : | ||
| Line 27: | Line 27: | ||
*** [[Intravenous]] drug abuse | *** [[Intravenous]] drug abuse | ||
*** Excessive [[alcohol]] intake | *** Excessive [[alcohol]] intake | ||
*** Early diagnosis and treatment of chronic liver disease <ref name="pmid20072996">{{cite journal |vauthors=Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J |title=[ALT screening for chronic liver diseases: scrutinizing the evidence] |language=German |journal=Z Gastroenterol |volume=48 |issue=1 |pages=46–55 |year=2010 |pmid=20072996 |doi=10.1055/s-0028-1109980 |url=}}</ref><ref name="pmid21256904">{{cite journal |vauthors=Breitling LP, Claessen H, Drath C, Arndt V, Brenner H |title=Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years |journal=J. Hepatol. |volume=55 |issue=3 |pages=594–601 |year=2011 |pmid=21256904 |doi=10.1016/j.jhep.2010.12.029 |url=}}</ref><ref name="pmid19967717">{{cite journal |vauthors=Claessen H, Brenner H, Drath C, Arndt V |title=Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany |journal=Hepatology |volume=51 |issue=2 |pages=482–90 |year=2010 |pmid=19967717 |doi=10.1002/hep.23324 |url=}}</ref><ref name="pmid19670414">{{cite journal |vauthors=Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H |title=Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels |journal=Hepatology |volume=50 |issue=5 |pages=1403–11 |year=2009 |pmid=19670414 |doi=10.1002/hep.23135 |url=}}</ref><ref name="pmid18684170">{{cite journal |vauthors=Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN |title=The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance |journal=Am. J. Gastroenterol. |volume=103 |issue=11 |pages=2727–36; quiz 2737 |year=2008 |pmid=18684170 |doi=10.1111/j.1572-0241.2008.02071.x |url=}}</ref> | *** Early diagnosis and treatment of [[chronic liver disease]] <ref name="pmid20072996">{{cite journal |vauthors=Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J |title=[ALT screening for chronic liver diseases: scrutinizing the evidence] |language=German |journal=Z Gastroenterol |volume=48 |issue=1 |pages=46–55 |year=2010 |pmid=20072996 |doi=10.1055/s-0028-1109980 |url=}}</ref><ref name="pmid21256904">{{cite journal |vauthors=Breitling LP, Claessen H, Drath C, Arndt V, Brenner H |title=Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years |journal=J. Hepatol. |volume=55 |issue=3 |pages=594–601 |year=2011 |pmid=21256904 |doi=10.1016/j.jhep.2010.12.029 |url=}}</ref><ref name="pmid19967717">{{cite journal |vauthors=Claessen H, Brenner H, Drath C, Arndt V |title=Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany |journal=Hepatology |volume=51 |issue=2 |pages=482–90 |year=2010 |pmid=19967717 |doi=10.1002/hep.23324 |url=}}</ref><ref name="pmid19670414">{{cite journal |vauthors=Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H |title=Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels |journal=Hepatology |volume=50 |issue=5 |pages=1403–11 |year=2009 |pmid=19670414 |doi=10.1002/hep.23135 |url=}}</ref><ref name="pmid18684170">{{cite journal |vauthors=Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN |title=The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance |journal=Am. J. Gastroenterol. |volume=103 |issue=11 |pages=2727–36; quiz 2737 |year=2008 |pmid=18684170 |doi=10.1111/j.1572-0241.2008.02071.x |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 18:18, 5 December 2017
|
Cirrhosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Cirrhosis primary prevention On the Web |
|
American Roentgen Ray Society Images of Cirrhosis primary prevention |
|
Risk calculators and risk factors for Cirrhosis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2] Sudarshana Datta, MD [3]
Overview
Primary prevention of cirrhosis includes avoidance of causative agents such as alcohol, high doses of certain supplements (vitamin A, copper and iron) and vaccination against hepatitis. Adequate caloric intake, physical activity, prevention of high risk behaviors, screening of blood products and vaccination for Hepatitis B play an important role in primary prevention.
Primary Prevention
- Methods of primary prevention include:
- Alcohol avoidance
- Physical exercise
- Smoking cessation[1]
- Adequate caloric intake[2]
- Avoid excessive consumption of:
- Vaccination for Hepatitis B [3]
- Education about hepatotoxins such as acetaminophen
- Prevention of obesity
- Screening of blood donors for Hepatitis B, Hepatitis C
- Familial screening for Wilson's disease, hemochromatosis
- Reduction of high-risk behaviors such as :
- Unprotected sexual intercourse
- Intravenous drug abuse
- Excessive alcohol intake
- Early diagnosis and treatment of chronic liver disease [4][5][6][7][8]
References
- ↑ Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ (2011). "Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease". J. Hepatol. 54 (4): 753–9. doi:10.1016/j.jhep.2010.07.040. PMC 3060962. PMID 21126792.
- ↑ Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, Hoofnagle JH (2010). "Increased caffeine consumption is associated with reduced hepatic fibrosis". Hepatology. 51 (1): 201–9. doi:10.1002/hep.23279. PMC 2801884. PMID 20034049.
- ↑ Eckman MH, Kaiser TE, Sherman KE (2011). "The cost-effectiveness of screening for chronic hepatitis B infection in the United States". Clin. Infect. Dis. 52 (11): 1294–306. doi:10.1093/cid/cir199. PMC 3097367. PMID 21540206.
- ↑ Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J (2010). "[ALT screening for chronic liver diseases: scrutinizing the evidence]". Z Gastroenterol (in German). 48 (1): 46–55. doi:10.1055/s-0028-1109980. PMID 20072996.
- ↑ Breitling LP, Claessen H, Drath C, Arndt V, Brenner H (2011). "Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years". J. Hepatol. 55 (3): 594–601. doi:10.1016/j.jhep.2010.12.029. PMID 21256904.
- ↑ Claessen H, Brenner H, Drath C, Arndt V (2010). "Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany". Hepatology. 51 (2): 482–90. doi:10.1002/hep.23324. PMID 19967717.
- ↑ Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H (2009). "Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels". Hepatology. 50 (5): 1403–11. doi:10.1002/hep.23135. PMID 19670414.
- ↑ Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN (2008). "The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance". Am. J. Gastroenterol. 103 (11): 2727–36, quiz 2737. doi:10.1111/j.1572-0241.2008.02071.x. PMID 18684170.